JT001
- Generic Name
- JT001
A Real-World Study of JT001 for COVID-19
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
- Target Recruit Count
- 7656
- Registration Number
- NCT06142201
- Locations
- 🇨🇳
Peking university first hospital, Beijing, Beijing, China
🇨🇳Gongli Hospital, Pudong New Area, Shanghai, Shanghai, Shanghai, China
🇨🇳Shanghai Fourth People's Hospital, Shanghai, Shanghai, China
JT001 (VV116) for the Treatment of COVID-19
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
- Target Recruit Count
- 1369
- Registration Number
- NCT05582629
- Locations
- 🇨🇳
The third people's hospital of Shenzhen, Shenzhen, Guangdong, China
🇨🇳Fuzhou Pulmonary Hospital Of Fujian, Fuzhou, Fujian, China
🇨🇳Wuhan Infections Diseases Hospital, Wuhan, Hubei, China
Efficacy and Safety of JT001 (VV116) Compared With Paxlovid
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Vigonvita Life Sciences
- Target Recruit Count
- 822
- Registration Number
- NCT05341609
- Locations
- 🇨🇳
Shanghai Pudong Hospital, Shanghai, Shanghai, China
🇨🇳ShuGuang Hospital, Shanghai, Shanghai, China
🇨🇳Huashan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
Efficacy and Safety of JT001 (VV116) Compared With Favipiravir
- Conditions
- Moderate to Severe COVID-19
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
- Target Recruit Count
- 290
- Registration Number
- NCT05279235
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
🇺🇿Specialized lnfectious Diseases Hospital No2 of Zangiota District, Tashkent, Tashkent Province, Uzbekistan
JT001 (VV116) for the Early Treatment of COVID-19
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Shanghai JunTop Biosciences Co., LTD
- Target Recruit Count
- 381
- Registration Number
- NCT05242042
- Locations
- 🇨🇳
Wuxi No.5 People's Hospital, Wuxi, Jiangsu, China
🇨🇳Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
🇨🇳Chongqing Public Health Medical Center, Chongqing, Chongqing, China
To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 256
- Registration Number
- NCT05101135
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.